ClinicalTrials.gg
RecruitingNCT06560957Updated May 1, 2026

SYNCED - SYNChronized Eating in Bipolar Depression Study

An interventional study of Time restricted eating and Eating ad libitum with nutritional counselling in Bipolar Depression, Bipolar I Disorder and Bipolar II Disorder, sponsored by University of Ottawa. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University of Ottawa · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Bipolar Disorder with a site in Canada — 24 open to participants now, 28 under way, 4 of them phase 3. Bipolar Disorder · Canada.

Planned enrollment
61st of 118
40 · median 42
Started
2025
with 5 others
No phase
57 of 134
16 open now
Primary completion
2026-12
later than 9 of 27 live
Registered
120th of 134
by date

Among the 134 studies in Bipolar Disorder with a site in Canada, this one is the 61st largest by planned enrollment of the 118 interventional ones that give a count, is one of 6 that started in 2025, is one of 57 with no phase, reaches primary completion later than 9 of the 27 other live ones, and was the 120th registered.

Bipolar Disorder

1,686 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

24 of the 134 studies in Bipolar Disorder with a site in Canada are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Bipolar Disorder with a site in Canada, or all of them as a file.
02

Study summary

Bipolar disorders (BD) are a group of complex disorders that impact mood, behaviour and cognition and are known to cause significant suffering and impairment. Circadian rhythm (your internal day/night "clock") disruption, which can involve changes in sleep-wake cycles, frequently occurs in BD. Both depression and mania are accompanied by circadian disruption. These disruptions are hypothesized to lead to mood worsening, metabolic dysfunction and inflammation. If circadian dysfunction plays a significant role in the symptoms and trajectory of BD, then treatment approaches that target these functions may lead to better outcomes. One such approach is dietary interventions. Time restricted eating (TRE) is a dietary tool that restricts the eating to an 8-12 hour window, without changing diet quality or caloric intake. Studies involving time restricted eating have been done in other conditions with promising results. There have been no studies done for mood disorders in general or bipolar disorder specifically. In this proposal, the investigators will assess two dietary interventions (TRE and nutritional counselling) to examine how TRE may represent a safe and viable adjunct to traditional treatments. The investigators aim to compare TRE with nutritional counselling, while all participants continue to receive usual care. Participants will receive support from a registered dietician and will be instructed on dietary habits. Half of participants will receive nutritional counselling and half will be asked to do TRE. Those in the TRE group will be asked to select a 10-hour window to consume all food and non-water beverages for the 8-week period. Participants will be asked to complete a screening visit to determine eligibility, and then will complete questionnaires at baseline, week 4 and week 8 examining symptoms of their illness and cognition. Participants will also provide a blood sample at baseline and week 8 for standard biochemistry tests, pregnancy testing (if applicable), and to examine inflammatory markers. Participants will also wear an actigraphy watch which provides wireless continuous monitoring of movements and ambient light. The primary outcome is feasibility and acceptability (do people agree to participate, complete the study, and follow the intervention; what do they think of the intervention). Secondary outcomes include changes in depression, anxiety, sleep, and cognition. Exploratory outcomes include inflammatory markers and circadian disruption.

Read the detailed description

Given the lack of studies evaluating time restricted eating (TRE), this pilot study aims to examine the feasibility and acceptability of TRE as a prelude to a future multi-centre randomized controlled trial (RCT) evaluating efficacy. If adjunctive TRE is found to be feasible, this will pave the way for a novel and safe intervention which may have the potential to treat circadian dysfunction, metabolic side effects and improve mood and cognitive outcomes in patients with BD.

To evaluate the feasibility and acceptability of adjunctive 10-hour TRE with treatment as usual relative to nutritional counselling and treatment as usual for the treatment of depression associated with bipolar disorder. To do this, the investigators will estimate the rate (proportion) of eligible people who are willing to participate, participants who drop out of the trial and participants who adhere to their allocated intervention.

First, the investigators hypothesize that the investigators would achieve our recruitment target of 40 patients with BD within the study's 18-month duration and retain at least 70% of participants through the follow-up period to evaluate feasibility. The investigators will also be able to estimate what level of adherence could be expected following a single intervention with a 4-week reminder. Second, the investigators hypothesize that participants would complete the intervention and find it acceptable.

Secondary Objectives To assess if TRE leads to meaningful reductions in markers of depression, anxiety, sleep, quality of life, and cognition.

The investigators hypothesize a greater reduction in depressive symptoms, anxiety symptoms compared to that seen in the control group. The investigators also hypothesize improvements in sleep, quality of life and cognition compared to the control group.

Exploratory Objectives Effects on inflammatory markers and circadian disruption will be additionally explored.

03

Conditions studied

  • Bipolar Depression
  • Bipolar I Disorder
  • Bipolar II Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be 18-55 years old
  2. Have a diagnosis of bipolar I or bipolar II disorder, confirmed by the Quick Structured Clinical Interview for ® Disorders, QuickSCID-5.
  3. Have depression symptoms as indicated by a score of ≥12 on MADRS and ≤12 on YMRS.
  4. Females of are willing to follow highly effective methods of (mentioned below) for the duration of study*
  5. Participants must be able to speak, read, write and understand English or French.
  6. Be willing and able to provide .

Exclusion criteria

Exclusion Criteria:

  1. Have any catatonic symptoms or eating disorder(s) as measured by the Quick Structured Clinical Interview for ® Disorders, QuickSCID-5.
  2. Have any unstable or inadequately treated neurological and medical conditions.
  3. Have had prior bariatric surgery. 4 Be taking hypoglycemia inducing medications.

5. Be pregnant or lactating. 6. Currently taking any stimulant medications. 7. Be participating in any other diet or weight management program for the duration of the trial.

8. Have any to fasting as judged by the assessing clinician. 9. Recently (i.e. within the past 8 weeks) began structured psychotherapy (i.e. cognitive-behavioral therapy, interpersonal psychotherapy, family-focused therapy, or interpersonal and social rhythm therapy).

10. Have any other medical condition, substance use disorder or suicidal ideation for which physician or investigator team expresses concern about safety or ability to participate in the study.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Group 1: Eating ad libitum, nutritional counselling plus treatment as usual

    Participants randomized to this group will be offered nutritional counselling from a registered dietician. They will also receive a check-in from the registered dietician at week 4. They will also continue to receive treatment as usual. Treatment as usual includes pharmacological treatment options such as mood stabilizers and/or atypical antipsychotics, and psychological treatments such as psychotherapy. No current treatments will be stopped to participate in the study. We will record changes made to the doses of medications during the trial. No new treatments will be started for the duration of the trial, including pharmacological and psychological treatments

    Behavioral: Eating ad libitum with nutritional counselling

  • Other
    Group 2:Time-restricted eating plus treatment as usual

    In addition to the nutritional counselling and continuing treatment as usual outlined in Group 1, this group will be provided time restricted eating instruction. The experimental group will be instructed to select a consistent 10-h eating window between 06:00 and 19:00 for all days of the week to consume all food and beverages (except water) for the duration of the 8-week intervention. Adherence to the intervention will be monitored weekly through phone check-ins with the research assistant. At 4-weeks, the study dietician will have a 1-hour check in with participants to review progress and adherence to TRE and to address any difficulties the participants may be facing.

    Behavioral: Time restricted eating

Interventions

  • BehavioralTime restricted eating

    Time restricted eating involves restricting the window in which calories are consumed to 8-10 hours, without altering diet quality or caloric intake. In this study, time restricted eating will be a consistent 10-h eating window between 06:00 and 19:00, considered an early TRE pattern, for all days of the week, as chosen by the participant. They will need to consume all food and beverages (except water) during this window for the duration of the 8-week intervention.

  • BehavioralEating ad libitum with nutritional counselling

    Nutritional counselling will include customized advice delivered by a registered dietician about dietary choices while allowing individuals to eat at any time of day.

06

What researchers measure

Primary outcomes

  1. Number of participants who complete the study

    The investigators will consider the intervention feasible if 70% of participants complete follow-up.

    Time frame: 18 months

  2. Time to recruit all participants

    The investigators will consider the intervention feasible if 70% of participants complete follow-up.

    Time frame: 18 months

  3. Intervention adherence

    The investigators will consider the intervention acceptable if participant adherence to the intervention is at least 70% (i.e. participants adhere to the TRE intervention 40 days out of 56 days); ii) at least 50% of participants approached about the study agree to participate.

    Time frame: 18 months

  4. Rate of participation

    The investigators will consider the intervention acceptable if at least 50% of potential participants approached about the study agree to participate.

    Time frame: 18 months

Secondary outcomes

  1. Depression severity - Montgomery-Åsberg Depression Rating Scale

    The Montgomery-Åsberg Depression Rating Scale (Structured Interview Guide) (MADRS) is a 10-item observer-rated scale to assess the severity of depressive symptoms within the last 7 days. Possible total score range is 0-60. Score of: 0-8 indicates remission/absent symptoms; 9-17 mild depression, 18-34 moderate depression; and 35-60 severe depression.

    Time frame: Screening, Baseline (week 1), Week 4, Week 8

  2. Cognitive dysfunction - Cognitive Complaints in Bipolar Disorder Rating Assessment

    A 16-item self-report that assess subjective cognitive dysfunction (including executive function, processing speed, working memory, verbal learning and memory, attention/concentration and mental tracking) in bipolar disorder. Measured on a 4-point Likert scale ranging from never (0) to always (3). Scores range 0-48 with higher scores indicating worse cognitive dysfunction.

    Time frame: Baseline (week 1), Week 4, Week 8

  3. Cognitive Dysfunction - Screen for Cognitive Impairment in Psychiatry

    The Screen for Cognitive Impairment in Psychiatry (SCIP) is a brief clinician administered evaluation of cognitive deficits including working memory, immediate and delayed verbal list learning, verbal fluency, and psychomotor speed. Score is calculated as a sum of 5 subgroups, with subgroup 3 having no limit to the total score. Total score ranges from 0 with no upper limit, with lower scores showing more cognitive impairment. These scores are interpreted in the following manner: total score of \< 75 suggest mild impairment, score of \< 65 indicate moderate impairment, and score of \< 55 indicate severe impairment.

    Time frame: Baseline (week 1), Week 4, Week 8

  4. Anxiety severity - Hamilton Anxiety Rating Scale

    The Hamilton Anxiety Rating Scale (HAM-A) is a 14-item semi-structured observer-rated interview evaluating symptoms of anxiety. Each item is scored 0 (not present) to - 4 (very severe). Scores range 0-56 with higher scoring indicating worse severity of anxiety symptoms. These scores are interpreted in the following manner: scores of 0-7 indicate remission/symptom absence, 8-14 mild anxiety, 15-23 moderate anxiety and 24-56 severe anxiety.

    Time frame: Baseline (week 1), Week 4, Week 8

  5. Anxiety severity - Generalized Anxiety Disorder-7

    Self-reported measurement of the severity of anxiety symptoms experienced within the last two weeks. It consists of 7 scored items and one follow-up question. Each of the 7 scored items generates a value from 0 (not at all) to 3 (nearly every day), yielding a total score ranging from 0 to 21, with higher scores indicating more severe symptoms of anxiety. These scores are interpreted in the following manner: a score of 0-4 indicates little or no anxiety, a score of 5-9 indicates mild anxiety, a score of 10-14 indicates moderate anxiety, and a score of 15-21 indicates severe anxiety. Generally, a score of 10 or above is considered to be a clinical cutoff implying that the respondent may be suffering from a general anxiety disorder.

    Time frame: Baseline (week 1), Week 4, Week 8

  6. Biological Rhythms - Biological Rhythm Interview for Assessment in Neuropsychiatry

    A 21-item observer-rated measure that assess five areas related to biological rhythms (sleep, activity, social aspect, diet, and predominant rhythm (chronotype)). All items are evaluated on a 4-point likert scale ranging from 1-4, with higher scores indicating greater disturbance. Total score ranges from 21-84.

    Time frame: Baseline (week 1), Week 4, Week 8

  7. Sleep Quality - Reduced Pittsburgh Sleep Quality Index

    The Pittsburgh Sleep Quality Index Questionnaire is self-administered questionnaire designed to evaluate sleep quality consisting of 18 items that in turn are comprised of seven components, which include subjective sleep quality, sleep duration, sleep onset, habitual sleep efficiency, sleep disturbances, use of sleeping medications and daytime dysfunction. Each weighted equally on a 0-3 scale to be summed to yield a global PSQI score, which ranges between 0 and 21, where the higher the scores, the worse the sleep quality. The investigators will only be using questions 1-4 and 6 (reduced PSQI).

    Time frame: Baseline (week 1), Week 4, Week 8

  8. 19-Item Self-Assessment Questionnaire for Sleep Rhythms, Habits and Fatigue (MEQ)

    This questionnaire has 19 questions, each with a number of points. Scores can range from 16-86. Scores of 41 and below indicate "evening types." Scores of 59 and above indicate "morning types." Scores between 42-58 indicate "intermediate types."

    Time frame: Baseline (week 1), Week 4, Week 8

  9. Function - Global Assessment of Functioning

    A numeric ranking between 0 and 100 that summarizes the clinician's view of the patient's current degree of impairment in terms of psychosocial and occupational or educational function. Higher scores indicate better functioning. Normal functioning typically ranges from 70-100.

    Time frame: Baseline (week 1), Week 4, Week 8

  10. Symptom Severity and Improvement - Clinical Global Impressions-BP-Severity & Improvement (CGI-BP I&S)

    The CGI-BP I\&S is a measure of CGI-I and CGI-S specifically validated for bipolar disorder. The CGI-BP-S scale provides a brief assessment of the severity of a patient's mental illness at baseline and following treatment. CGI-I and CGI-S are each rated on a likert scale of 0-7 (0, not assessed, 1-7 normal to most extremely ill). The CGI-BP-I scale provides a brief assessment of a patient's overall mental state following treatment, and whether or not it is due entirely to the experimental treatment.

    Time frame: Baseline (week 1), Week 4, Week 8

  11. Psychological Dysfunction - Functioning assessment short test (FAST)

    The FAST is a brief clinician-reported scale which assess psychosocial dysfunction across multiple domains (autonomy, occupational functioning, cognitive functioning, financials, interpersonal relationships, and leisure time) in people with bipolar disorder. Aspects of functioning are rated on a 4-point Likert scale of 0 (no difficulty) to 3 (severe difficulty) with total scores ranging from 0-72. Higher scores indicate more dysfunction.

    Time frame: Baseline (week 1), Week 4, Week 8

  12. Quality of Life - Brief Quality of Life in Bipolar Disorder Questionnaire

    A brief 12-item self report that examines quality of life in people living with bipolar disorder over the past 7 days. Experiences of quality of life are rated on a 5-point Likert scale ranging from 1 (Strongly disagree) to 5 (Strongly Agree). Total scores range from 12-60 with higher scores indicating better quality of life.

    Time frame: Baseline (week 1), Week 4, Week 8

  13. Mania severity - Young Mania Rating Scale

    The Young Mania Rating Scale is used to evaluate the severity of manic symptoms at baseline and over time in individuals with mania. It is an 11-item scale and total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania).

    Time frame: Screening, Baseline (week 1), Week 4, Week 8

Other outcomes

  1. Change in circadian rhythms

    Using wrist actigraphy, the investigators will collect data on two 24-hour sleep-wake cycles. The validated wrist actigraphy monitor will collect non-invasive, wireless continuous monitoring of movements and ambient light (in the blue, green and red spectrum). These two measures will be combined to extract sleep estimates and parameters of the 24-hour activity-rest cycle before and after the intervention. Changes in the circadian rhythms (hours of sleep or movement) will be compared pre- and post between treatment groups.

    Time frame: Week 0, Week 9

  2. Change in C-reactive protein levels

    The investigators will collect blood samples and measure levels of C-reactive protein (CRP) before and after the intervention. CRP is an inflammation marker and measured in mg/L.

    Time frame: Baseline (week 1), Week 8

  3. Change in cytokine levels

    The investigators may collect blood samples and measure levels of cytokines including interleukins (IL) -6, IL-10, IL-1B and tumor necrosis factor alpha (TNF-a) before and after the intervention. IL-6, IL-10 and TNF-a are inflammatory cytokines and IL-10 is an anti-inflammation cytokine. All cytokines are measured in pg/mL.

    Time frame: Baseline (week 1), Week 8

  4. Change in red blood cell count

    The investigators will collect blood samples to evaluate changes in red blood cell count (RBC) as part of changes in hematology before and after intervention. This will be done as part of a complete blood count (CBC) will be conducted to investigate changes in various blood components. RBC is measured in x10\*12/L

    Time frame: Baseline (week 1), Week 8

  5. Change in hemoglobin

    The investigators will collect blood samples to evaluate changes in hemoglobin (Hgb) as part of changes in hematology before and after intervention. This will be done as part of a complete blood count (CBC) will be conducted to investigate changes in various blood components. Hgb is measured in g/L.

    Time frame: Baseline (week 1), Week 8

  6. Change in hematocrit

    The investigators will collect blood samples to evaluate changes in hematocrit (Hct) as part of changes in hematology before and after intervention. This will be done as part of a complete blood count (CBC) will be conducted to investigate changes in various blood components. Hct is measured in L/L..

    Time frame: Baseline (week 1), Week 8

  7. Change in lymphocyte count

    The investigators will collect blood samples to evaluate changes in lymphocyte count as part of changes in hematology before and after intervention. This will be done as part of a complete blood count (CBC) will be conducted to investigate changes in various blood components. Lymphocyte count is measured in x10\*9/L.

    Time frame: Baseline (week 1), Week 8

  8. Change in blood chemistry

    The investigators may collect blood samples to evaluate changes in blood chemistry before and after the intervention. The test will include fasting glucose, fasting lipid profile (includes measures of high-density and low-density lipoprotein cholesterol, total cholesterol and triglycerides). All blood chemistry measures are measured in mmol/L.

    Time frame: Baseline (week 1), Week 8

  9. Change in liver functions

    The investigators may collect blood samples to evaluate changes in liver function by measuring alkaline phosphatase (ALP), aspartate transferase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT) before and after the intervention. All measures are reported in U/L.

    Time frame: Baseline (week 1), Week 8

  10. Change in total bilirubin

    The investigators may collect blood samples to evaluate changes in liver function by measuring total bilirubin before and after the intervention. This is measured in umol/L.

    Time frame: Baseline (week 1), Week 8

  11. Change in serum creatinine

    The investigators will collect blood samples to evaluate changes in blood chemistry by measuring total serum creatinine before and after the intervention. This is measured in umol/L.

    Time frame: Baseline (week 1), Week 8

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 17 months is below that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Aug 19, 2024
StartActual
Jul 10, 2025
Primary completionEst.
Dec 26, 2026
CompletionEst.
Feb 26, 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06560957
Responsible party
Gayatri Saraf (Psychiatrist and Associate Professor, University of Ottawa) — Principal investigator
First posted
Aug 19, 2024
Start date
Jul 10, 2025
Primary completion
Dec 26, 2026 (estimated)
Completion
Feb 26, 2027 (estimated)
Last update
May 1, 2026

Study contacts

Deniz Ruscuklu, BA
Contact
deruscuklu@ohri.ca
613-737-8899 ext. 85568
Gayatri Saraf, MD
Contact
gsaraf@toh.ca
Gayatri Saraf, MD
principal investigator · The Ottawa Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion